Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3214996 in Relapsed or Refractory AML
NCT04081259Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of temuterkib in acute myeloid leukemia (AML) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Jul 2020; status: completed.
02
Drugs
temuterkib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04081259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081259.